Management strategies for gastroesophageal reflux disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bak, YT | - |
dc.date.available | 2020-12-09T10:42:26Z | - |
dc.date.created | 2020-10-19 | - |
dc.date.issued | 2004-09 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/36472 | - |
dc.description.abstract | In the treatment of gastroesophageal reflux disease (GERD), the most effective treatment option is the use of proton pump inhibitor (PPI), which minimizes the effect of gastric acid on the distal esophagus. Both the step-up and step-down treatment strategies have advantages and disadvantages. Most physicians would like to choose the step-down therapy rather than the step-up therapy. The 'No-step' PPI therapy (i.e. continuous PPI therapy) is another relevant option. After an initial remission, long-term PPI therapy is an appropriate form of maintenance therapy in many patients. As a treatment plan for non-erosive reflux disease, a standard dose of PPI for 4-8 weeks followed by either the step-down strategy or the on-demand treatment strategy is acceptable. When treating erosive esophagitis, PPI is better than H-2 receptor blockers in healing mucosal breaks and relieving symptoms. Long-term maintenance PPI therapy is reported to be very effective in maintaining the remission of reflux esophagitis for up to 5 years. On-demand PPI is also another good option for a maintenance therapy in erosive esophagitis. In Barrett's esophagus, symptoms seem to be well-controlled with PPIs. Unfortunately, however, PPIs have no effect on the shortening of Barrett's esophagus or in preventing the progression to dysplasia and adenocarcinoma. In summary, after reviewing existing guidelines a rather simple guideline on the management of GERD is suggested - PPI should be given for 4-8 weeks followed by either on-demand or maintenance PPI therapy according to the clinical severity. (C) 2004 Blackwell Publishing Asia Pty Ltd. | - |
dc.language | 영어 | - |
dc.publisher | WILEY | - |
dc.subject | DOUBLE-BLIND TRIAL | - |
dc.subject | COST-EFFECTIVENESS | - |
dc.subject | 20 MG | - |
dc.subject | GUIDELINES | - |
dc.subject | CONSENSUS | - |
dc.subject | EFFICACY | - |
dc.subject | THERAPY | - |
dc.subject | ARTICLE | - |
dc.subject | ESOPHAGITIS | - |
dc.subject | OMEPRAZOLE | - |
dc.title | Management strategies for gastroesophageal reflux disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bak, YT | - |
dc.identifier.doi | 10.1111/j.1440-1746.2004.03587.x | - |
dc.identifier.scopusid | 2-s2.0-4544352548 | - |
dc.identifier.wosid | 000223471500006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.19, pp.S49 - S53 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 19 | - |
dc.citation.startPage | S49 | - |
dc.citation.endPage | S53 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | DOUBLE-BLIND TRIAL | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS | - |
dc.subject.keywordPlus | 20 MG | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ARTICLE | - |
dc.subject.keywordPlus | ESOPHAGITIS | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordAuthor | gastroesophageal reflux disease | - |
dc.subject.keywordAuthor | management strategy | - |
dc.subject.keywordAuthor | proton pump inhibitor | - |
dc.subject.keywordAuthor | maintenance therapy | - |
dc.subject.keywordAuthor | on-demand therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841) 82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.